Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs

REFERENCES

1. 1.↵
   1. Gladman DD

   . Recent advances in understanding and managing psoriatic arthritis. F1000Res 2016;5:2670.

   OpenUrl
2. 2.↵
   1. Sokoll KB,
   2. Helliwell PS

   . Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842–6.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Borman P,
   2. Toy GG,
   3. Babaoğlu S,
   4. Bodur H,
   5. Ciliz D,
   6. Alli N

   . A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007;26:330–4.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Coates LC,
   2. Tillett W,
   3. Chandler D,
   4. Helliwell PS,
   5. Korendowych E,
   6. Kyle S,
   7. et al;
   8. BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR

   . The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology 2013;52:1754–7.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. National Institute for Health and Care Excellence

   . Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. Technology Appraisal Guidance. [Internet. Accessed December 12, 2019.] Available from: www.nice.org.uk/guidance/ta199/resources/etanercept-infliximab-and-adalimumab-for-the-treatment-of-psoriatic-arthritis-82598565006277
6. 6.↵
   1. Coates LC,
   2. Kavanaugh A,
   3. Mease PJ,
   4. Soriano ER,
   5. Laura Acosta-Felquer M,
   6. Armstrong AW,
   7. et al.

   Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68:1060–71.

   OpenUrl
7. 7.↵
   1. Lajas C,
   2. Abasolo L,
   3. Bellajdel B,
   4. Hernández-Garcia C,
   5. Carmona L,
   6. Vargas E,
   7. et al.

   Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64–70.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Kobelt G,
   2. Woronoff AS,
   3. Richard B,
   4. Peeters P,
   5. Sany J

   . Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR study. Joint Bone Spine 2008;75:408–15.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Rodgers M,
   2. Epstein D,
   3. Bojke L,
   4. Yang H,
   5. Craig D,
   6. Fonseca T,
   7. et al.

   Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15:i–xxi, 1–329.

   OpenUrl
10. 10.↵
    1. Poole CD,
    2. Lebmeier M,
    3. Ara R,
    4. Rafia R,
    5. Currie CJ

    . Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology 2010;49:1949–56.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H;
    7. CASPAR Study Group

    . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Tillett W,
    2. Costa L,
    3. Jadon D,
    4. Wallis D,
    5. Cavill C,
    6. McHugh J,
    7. et al.

    The ClASsification for Psoriatic Arthritis (CASPAR) criteria — a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012;39:154–6.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Fries JF,
    2. Spitz P,
    3. Kraines RG,
    4. Holman HR

    . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Bruce B,
    2. Fries JF

    . The Stanford Health Assessment Questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167–78.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Bruce B,
    2. Fries JF

    . The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. UK Government

    . NHS reference costs 2014 to 2015. [Internet. Accessed December 12, 2019.] Available from: www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015
17. 17.↵
    1. Curtis L,
    2. Burns B

    . Unit costs of health and social care 2016. [Internet. Accessed December 12, 2019.] Available from: www.pssru.ac.uk/pub/uc/uc2016/full.pdf?uc=2016-full
18. 18.↵
    1. British Medical Association and The Royal Pharmaceutical Society

    . British National Formulary Website. [Internet. Accessed December 12, 2019.] Available from: www.evidence.nhs.uk/formulary/bnf/current
19. 19.↵
    1. National Health Service Business Services Authority

    . Drug tariff. [Internet. Accessed December 12, 2019.] Available from: www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff
20. 20.↵
    1. R Core Team

    . R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet. Accessed December 12, 2019.] Available from: www.R-project.org
21. 21.↵
    1. Husted J,
    2. Gladman D,
    3. Farewell V,
    4. Cook R

    . Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45:151–8.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Lindqvist U,
    2. Alenius GM,
    3. Husmark T,
    4. Theander E,
    5. Holmström G,
    6. Larsson PT,
    7. et al;
    8. Psoriatic Arthritis Group of the Society for Rheumatology

    . The Swedish early psoriatic arthritis register — 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668–73.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Kristensen LE,
    2. Jørgensen TS,
    3. Christensen R,
    4. Gudbergsen H,
    5. Dreyer L,
    6. Ballegaard C,
    7. et al.

    Societal costs and patients’ experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis 2017;76:1495–501.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Burgos-Pol R,
    2. Martínez-Sesmero JM,
    3. Ventura-Cerdá JM,
    4. Elías I,
    5. Caloto MD,
    6. Casado MÁ

    . The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr 2016;107:577–90.

    OpenUrl
25. 25.↵
    1. Kawalec P,
    2. Malinowski KP

    . The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2015;15:125–32.

    OpenUrl
26. 26.↵
    1. Kawalec P,
    2. Malinowski KP,
    3. Pilc A

    . Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatol Int 2016;36:1223–30.

    OpenUrl
27. 27.↵
    1. Tillett W,
    2. de-Vries C,
    3. McHugh NJ

    . Work disability in psoriatic arthritis: a systematic review. Rheumatology 2012;51:275–83.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Tillett W,
    2. Shaddick G,
    3. Askari A,
    4. Cooper A,
    5. Creamer P,
    6. Clunie G,
    7. et al.

    Factors influencing work disability in psoriatic arthritis: first results form a large UK multicentre study. Rheumatology 2015;54:157–62.

    OpenUrlCrossRefPubMed